Lamivudine Therapy Exacerbates Bilirubinemia in Patients Underlying Severely Advanced Hepatitis

  • Choi, Young Hee (College of Pharmacy, Dongguk University_Seoul) ;
  • Lee, Chang Ho (Department of Pharmacology, College of Medicine, Hanyang University) ;
  • Ko, Myong Suk (Korea Intellectual Property Strategy Agency, Business Cooperation Team) ;
  • Han, Hyun Joo (Department of Pharmacy, Seoul National University Hospital) ;
  • Kim, Sang Geon (Department of Pharmacy, Seoul National University Hospital)
  • Received : 2017.09.12
  • Accepted : 2017.09.25
  • Published : 2017.10.15


Lamivudine belongs to the set of antiviral agents effective against hepatitis B virus infection. Given case reports on liver injuries after certain antiviral agent treatments, this study examined the effects of lamivudine on alanine aminotransferase (ALT) and total bilirubin (TB) using a medical system database. A total of 1,321 patients taking lamivudine alone or with others were evaluated using laboratory hits in an electronic medical system at Seoul National University Hospital from 2005 through 2011. The patients were grouped according to prior ALT results: G#1, ALT < 40 IU/L; G#2, 40 IU/L ${\leq}$ ALT < 120 IU/L; G#3, 120 IU/L ${\leq}$ ALT < 240 IU/L; and G#4, ALT ${\geq}$ 240 IU/L. In G#1 and G#2 patients, lamivudine or adefovir treatment decreased ALT and TB compared to prior values. In G#3 and G#4 patients with three times the upper limit of normal (ULN) ${\leq}$ ALT < 15 times the ULN, both ALT and TB were decreased after treatment with lamivudine alone, or adefovir following lamivudine therapy, indicating that lamivudine therapy ameliorated liver functions. However, in G#4 patients who experienced severely advanced hepatitis (ALT ${\geq}$ 15 times the ULN, or ${\geq}$ 600 IU/L), lamivudine augmented TBmax ($6.3{\rightarrow}13.3mg/dL$) despite a slight improvement in ALT ($839{\rightarrow}783IU/L$), indicative of exacerbation of bilirubinemia. Patients who used adefovir after lamivudine also showed a high incidence of hyperbilirubinemia when they experienced severely advanced hepatitis. Treatment with adefovir alone did not show the effect. In conclusion, lamivudine may increase the risk of hyperbilirubinemia in patients with severely advanced hepatitis, implying that caution should be exercised when using lamivudine therapy in certain patient populations.


Supported by : Seoul National University Hospital


  1. Uglietti, A., Zanaboni, D., Gnarini, M. and Maserati, R. (2013) Emtricitabine/tenofovir in the treatment of HIV infection: current PK/PD evaluation. Expert Opin. Drug Metab. Toxicol., 8, 1305-1314.
  2. Andreea, F. and Marius, B. (2009) Adverse drug reactions in clinical practice: a causality assessment of a case of druginduced pancreatitis. J. Gastrointest. Liver Dis., 18, 353-358.
  3. Jha, A.K., Kuperman, G.J., Teich, J.M., Leape, L., Shea, B., Rittenberg, E., Burdick, E., Seger, D.L., Vander Vliet, M. and Bates, D.W. (1998) Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report. J. Am. Med. Inform. Assoc., 5, 305-314.
  4. Kohn, L.T., Corrgan, J.M. and Donaldson, M.S. (1999) To Err in Human: Building a Safer Health System, National Academy Press, Washington, D.C.
  5. Lee, Y.H., Kang, U.G. and Park, R.W. (2008) Development of adverse drug event surveillance system using BI technology. Int. J. Contents, 9, 106-113.
  6. Rodriguez-Monguio, R., Otero, M.J. and Rovira, J. (2003) Assessing the economic impact of adverse drug effects. Pharmacoeconomics, 21, 623-650.
  7. Tisdale, J.E. and Miller, D.A. (2005) Drug-Induced Diseases. Prevention, Detection and Management, Ameritan Society of Health-System Pharmacist Press, Bethesda, Maryland, p. 1004.
  8. Verhaz, A. (2014) Experience with lamivudine treatment for severe acute hepatitis B. Srp. Arh. Celok. Lek., 142, 703-707.
  9. Ah, Y.M., Kim, Y.H., Kim, M.-J., Choi, Y.H., Park, K.H., Son, I.J. and Kim, S.G. (2008) Drug-induced hyperbilirubinemia and the clinical influencing factors. Drug Metab. Rev., 40, 511-537.
  10. Kaplowitz, N. (2003) Drug-induced liver disorders: introduction and overview in Drug-Induced Liver Disease (Kaplowitz, N. and Deleve, L.D. Eds.). Marcel Dekker Inc., New York, pp. 150-158.
  11. Zimmerman, H.J. (1999) Hepatotoxicity. The Adverse Effects of Drugs and Other Chemicals on the Liver (2nd edition), Lippincott Williams & Wilkins, Philadelphia, pp. 235-249.
  12. Pradeep Kumar, S., Medhi, S., Asim, M., Das, B.C., Gondal, R. and Kar, P. (2011) Evaluation of adefovir & lamivudine in chronic hepatitis B: correlation with HBV viral kinetic, hepatic-necro inflammation & fibrosis. Indian J. Med. Res., 133, 50-56.
  13. Kudo, M., Todo, A., Ikekubo, K., Hino, M., Yonekura, Y., Yamamoto, K. and Torizuka, K. (2014) Functional hepatic imaging with receptor-binding radiopharmaceutical: clinical potential as a measure of functioning hepatocyte mass. Gastroenterol. Jpn., 26, 734-741.
  14. Rowland, A., Mackenzie, P.I. and Miners, J.O. (2015) Transporter-mediated uptake of UDP-glucuronic acid by human liver microsomes: assay conditions, kinetics, and inhibition. Drug Metab. Dispos., 43, 147-153.
  15. Wan, Z., Wu, Y., Yi, J., You, S., Liu, H., Sun, Z., Zhu, B., Zang, H., Li, C., Liu, F., Li, D., Mao, Y. and Xin, S. (2015) Combining serum cystatin C with total bilirubin improves short-term mortality prediction in patients with HBV-related acute-on-chronic liver failure. PLoS ONE, 10, e0116968.
  16. Tsubota, A., Arase, Y., Saitoh, S., Kobayashi, M., Suzuki, Y., Suzuki, F., Chayama, K., Murashima, N., Ikeda, K., Kobayashi, M. and Kumada, H. (2001) Lamivudine therapy for spontaneously occurring severe acute exacerbation in chronic hepatitis B virus infection: a preliminary study. Am. J. Gastroenterol., 96, 557-562.
  17. Pirmohamed, M., James, S., Meakin, S., Green, C., Scott, A.K., Walley, T.J., Farrar, K., Park, B.K. and Breckenridge, A.M. (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ, 329, 15-19.
  18. Lazarous, J., Pomeranz, B. and Corey, P.N. (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA, 279, 1200-1205.
  19. Mauben, M., Madigan, D., Gerritis, C.M. (2007) The role of data mining in pharmacovigilance. Expert Opin. Drug Saf., 14, 929-948.
  20. Barcena, R., Del Campo, S., Moraleda, G., Casanovas, T., Prieto, M., Buti, M., Moreno, J.M., Cuervas, V., Fraga, E., De la Mata, M., Otero, A., Delgado, M., Loinaz, C., Barrios, C., Dieguez, M.L., Mas, A., Sousa, J.M., Herrero, J.I., Muñoz, R., Avilés, J.F., Gonzalez, A. and Rueda, M. (2005) Study on the efficacy and safety of adefovir dipivoxil treatment in postliver transplant patients with hepatitis B virus infection and lamivudine-resistant hepatitis B virus. Transplant. Proc., 37, 3960-3962.
  21. Ben-Ari, Z., Mor, E. and Tur-Kaspa, R. (2003) Experience with lamivudine therapy for hepatitis B virus infection before and after liver transplantation, and review of the literature. J. Intern. Med., 253, 544-552.
  22. Liu, C., Ye, J., Jia, H., Zhang, M., Han, H., Chen, F. and Chen, C. (2013) Entecavir and lamivudine therapy for severe acute chronic hepatitis B. Exp. Ther. Med., 5, 545-548.
  23. Bonkovsky, H.L., Azar, R., Bird, S., Szabo, G. and Banner, B. (2002) Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone. Dig. Dis. Sci., 47, 1632-1637.
  24. Brickford, C.L. and Spencer, A.P. (2005) Biliary sludge and hyperbilirubinemia associated with ceftriaxone in an adult: case report and review of the literature. Pharmacotherapy, 25, 1389-1395.
  25. Thompson, P.D., Clarkson, P. and Karas, R.H. (2003) Statinassociated myopathy. JAMA, 289, 1681-1690.
  26. Willens, H.J. (2000) Clopidogrel-induced mixed hepatocellular and cholestatic liver injury. Am. J. Ther., 7, 317-318.
  27. Cousins, D. and Baker, M. (2004) The work of the National Patient Safety Agency to improve medication safety. Br. J. Gen. Pract., 54, 331-333.
  28. Wang, G.L., Liu, Y., Qiu, P., Zhou, S.F., Xu, L.F., Wen, P., Wen, J.B. and Xiao, X.Z. (2016) Cost-effectiveness of Lamivudine, Telbivudine, Adefovir Dipivoxil and Entecavir on decompensated hepatitis B virus-related cirrhosis. Eur. Rev. Med. Pharmacol. Sci., 20, 866-872.
  29. Korenblat, K.M. and Berk, P.D. (2005) Hyperbilirubinemia in the setting of antiviral therapy. Clin. Gastroenterol. Hepatol., 3, 303-310.
  30. Zhang, C., Ke, W., Liu, L., Gao, Y., Yao, Z., Ye, X., Zhou, S. and Yang, Y. (2016) Cost-effectiveness comparison of lamivudine plus adefovir combination treatment and nucleos(t)ide analog monotherapies in Chinese chronic hepatitis B patients. Drug Des. Devel. Ther., 10, 897-910.
  31. Leung, N.W.Y., Lai, C.-L., Chang, T.-T., Guan, R., Lee, C.-M., Ng, K.-Y., Lim, S.-G., Wu, P.C., Dent, J.C., Edmundson, S., Condreay, L.D. and Chien, R.N. (2001) Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology, 33, 1527-1532.
  32. Li, X., Jie, Y., You, X., Shi, H., Zhang, M., Wu, Y., Lin, G., Li, X., Gao, Z. and Chong, Y. (2015) Optimized combination therapies with adefovir dipivoxil (ADV) and lamivudine, telbivudine, or entecavir may be effective for chronic hepatitis B patients with a suboptimal response to ADV monotherapy. Int. J. Clin. Exp. Med., 8, 21062-21070.
  33. Perrillo, R., Schiff, E., Yoshida, E., Statler, A., Hirsch, K., Wright, T., Gutfreund, K., Lamy, P. and Murray, A. (2000) Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology, 32, 129-134.
  34. Peters, M.G., Hann, H.W., Martin, P., Heathcote, E.J., Buggisch, P., Rubin, R., Bourliere, M., Kowdley, K., Trepo, C., Gray, D.F., Sullivan, M., Kleber, K., Ebrahimi, R., Xiong, S. and Brosgart, C.L. (2004) Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology, 126, 91-101.